Standout Papers

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis 2022 2026 2023 2024124
  1. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis (2022)
    Philip J. Mease, Atul Deodhar et al. Annals of the Rheumatic Diseases

Immediate Impact

5 from Science/Nature 57 standout
Sub-graph 1 of 22

Citing Papers

Colorectal cancer
2024 Standout
Deuterium in drug discovery: progress, opportunities and challenges
2023 Standout
1 intermediate paper

Works of Jonghyeon Kim being referenced

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
2022 Standout
Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials
2008

Author Peers

Author Last Decade Papers Cites
Jonghyeon Kim 653 301 89 215 28 1.3k
R D Situnayake 132 110 77 381 28 1.2k
Ardon Rubinstein 90 100 152 58 45 1.2k
Katayoon B. Ebrahimi 967 375 121 43 30 1.4k
Patrick M. Moriarty 73 65 91 56 39 1.6k
Everson Nogoceke 563 434 409 22 32 1.7k
Di Wu 229 354 171 12 50 1.3k
Dietmar Schwab 358 281 41 34 26 1.1k
Tova Chajek 505 9 162 249 31 1.6k
Monica Maria Pagliara 433 221 216 9 47 1.3k
Xiaohong Yang 53 40 256 61 48 1.7k

All Works

Loading papers...

Rankless by CCL
2026